



LEGISLATIVE BLACK CAUCUS OF MARYLAND, INC.

The Maryland House of Delegates, 6 Bladen Street, Room 300, Annapolis, Maryland 21401
410-841-3185 • 301-858-3185 • 800-492-7122 Ext. 3185 • Fax 410-841-3175 • 301-858-3175 • Black.Caucus@house.state.md.us

EXECUTIVE OFFICERS

Chair

Delegate Jheanelle Wilkins, District 20

1st Vice Chair

 February 6, 2025

Delegate Melissa Wells, District 40

2nd Vice Chair

Delegate Karen R. Tolos, District 25

Treasurer

Delegate Marlon Amprey, District 40

Secretary

Delegate Jamila J. Woods, District 26

Financial Secretary

Senator Arthur Ellis, District 28

Chaplain

Delegate Jeffrie E. Long, Jr., District 27B

Parliamentarian

Delegate Stephanie Smith, District 45

Historian

Delegate Cheryl E. Pasteur, District 11A

Executive Director

Ufuoma O. Agarin, J.D.

February 6, 2025

Chair Pamela Beidle
Finance Committee
2 East Miller Senate Office Building
Annapolis, Maryland 21401

Dear Chair Beidle and Members of the Committee,

The Legislative Black Caucus of Maryland strongly supports Senate Bill 357 (SB0357) – Lowering Prescription Drug Costs for All Marylanders Now Act. This bill introduces essential reforms to Maryland’s prescription drug pricing system, ensuring that all residents who are disproportionately impacted by high healthcare costs have access to affordable medications. **Senate Bill 357 is a 2025 Black Caucus legislative priority bill.**

The United States has witnessed alarming instances of pharmaceutical price gouging, which have severely impacted patient access to essential medications. A notable example occurred in 2015 when Turing Pharmaceuticals, under CEO Martin Shkreli, acquired the rights to Daraprim, an essential medication used to treat and prevent malaria and HIV among other uses. Within a month, the company increased the price from \$13.50 to \$750 per pill, an astronomical hike of over 5,000%. This exorbitant increase placed a life-saving medication out of reach for many patients.

In contrast, countries such as Australia and South Korea have implemented effective government oversight to regulate drug prices while maintaining pharmaceutical innovation. Australia’s Pharmaceutical Benefits Scheme (PBS) uses an independent review board to assess drug prices and negotiate fair costs with manufacturers, ensuring affordability without restricting access. Similarly, South Korea’s National Health Insurance system negotiates drug prices with pharmaceutical companies to keep medications affordable while ensuring quality care. These models demonstrate that strong regulatory frameworks can reduce drug prices without stifling medical advancements.

The issue of high prescription drug costs hits Black communities particularly hard, exacerbating existing health disparities. Black Marylanders are more likely to suffer from chronic conditions like hypertension, diabetes, and cardiovascular disease, all of which require ongoing medication. However, the high cost of these prescriptions creates treatment gaps that further deteriorate health outcomes. A Kaiser Family Foundation poll revealed that 61% of Black adults are concerned about affording prescription drugs, compared to 50% of White adults,

MEMBERS

Senator Malcolm Augustine, District 47
Senator Benjamin Brooks, District 10
Senator Jill P. Carter, District 41
Senator Nick Charles, District 25
Senator Antonio L. Hayes, District 40
Senator Michael A. Jackson, District 27
Senator Cory V. McCray, District 45
Senator C. Anthony Muse, District 26
Senator William C. Smith, Jr., District 20
Senator Charles E. Sydnor III, Esq., District 44
Senator Alonzo T. Washington, District 22
Senator Mary L. Washington, District 43
Senator Ron Watson, District 23
Delegate Gabriel Acevero, District 39
Delegate Jacqueline T. Addison, District 45
Delegate Tiffany Alston, District 24
Delegate Vanessa E. Attarbear, District 13
Delegate J. Sandy Bartlett, District 32
Delegate Adrian Boatof, District 23
Delegate Regina T. Boyce, District 43A
Delegate Frank M. Canaway, Jr., District 40
Delegate Charlotte Crutchfield, District 19
Delegate Dabra Davis, District 28
Delegate Diana M. Fennell, District 47A
Delegate Kevin M. Harris, District 27A
Delegate Andrea Fletcher Harrison, District 24
Delegate Shaneka Henson, District 30A
Delegate Terri L. Hill, District 12
Delegate Marvin E. Holmes, Jr., District 23
Delegate Julian Ivey, District 47A
Delegate Carl Jackson, District 8
Delegate Andre V. Johnson, Jr., District 34A
Delegate Adrienne A. Jones, District 10
Delegate Jazz Lewis, District 24
Delegate Robbyn Lewis, District 46
Delegate Ashanti Martinez, District 22
Delegate Aletheia McCaskill, District 44B
Delegate Bernice Mireku-North, District 14
Delegate Edith J. Patterson, District 28
Delegate Joseline Peña-Melnyk, District 21
Delegate N. Scott Phillips, District 10
Delegate Pamela Queen, District 14
Delegate Kent Roberson, District 25
Delegate Denise G. Roberts, District 25
Delegate Mike Rogers, District 32
Delegate Malcolm P. Ruff, District 41
Delegate Gary Simmons, District 12B
Delegate Dani Tavaras, District 47B
Delegate Kym Taylor, District 23
Delegate Veronica Turner, District 26
Delegate Jennifer White Holland, District 10
Delegate Nicole A. Williams, District 22
Delegate C.T. Wilson, District 28
Delegate Greg Wims, District 39
Delegate Caylin Young, District 45

highlighting the urgency for legislative action. In addition, the CDC reported that over 9 million Americans aged 18-64 skip doses, take smaller amounts, or delay refills due to cost. This practice disproportionately affects lower-income Black families, leading to worsened health conditions and higher long-term healthcare costs.

Black Marylanders are also more likely to rely on state health programs than their White counterparts. As prescription costs rise, these programs face increased strain, leading to delays in care and formularies that may exclude critical medications. By reducing drug prices through regulatory oversight, SB0357 will provide direct benefits to Black Marylanders who depend on Medicaid and other public health programs to afford necessary treatments.

Rather than imposing a blanket price cap, SB0357 adopts an equitable approach by establishing a Prescription Drug Affordability Board. This board will thoroughly assess and evaluate drug costs before setting upper payment limits, ensuring that price regulations are based on real affordability challenges. Additionally, the board's structure allows for continuous oversight, meaning it can adjust pricing policies in response to market changes—avoiding the risks of a rigid, outdated price cap that could become ineffective over time.

By prioritizing affordability, healthcare equity, and economic relief for communities most affected by high drug prices, SB0357 advances the principles of justice and fairness. The bill reflects the Caucus' commitment to tackling systemic healthcare disparities and advocating for reforms that uplift Black Marylanders.

Senate Bill 357 represents a critical step in making prescription medications more affordable and accessible for all Marylanders. It balances public health needs with fiscal responsibility while ensuring that Maryland's most vulnerable populations receive the care they deserve. For these reasons, the Legislative Black Caucus of Maryland strongly supports Senate Bill 357 and urges this committee to make a favorable report.

Legislative Black Caucus of Maryland